ATE332364T1 - Verfahren zur gewinnung von purifizierter virenzuammensetzung - Google Patents

Verfahren zur gewinnung von purifizierter virenzuammensetzung

Info

Publication number
ATE332364T1
ATE332364T1 AT00906444T AT00906444T ATE332364T1 AT E332364 T1 ATE332364 T1 AT E332364T1 AT 00906444 T AT00906444 T AT 00906444T AT 00906444 T AT00906444 T AT 00906444T AT E332364 T1 ATE332364 T1 AT E332364T1
Authority
AT
Austria
Prior art keywords
purified virus
virus composition
obtaining purified
viral
particles
Prior art date
Application number
AT00906444T
Other languages
English (en)
Inventor
Michel Koehl
David Gaillac
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE332364T1 publication Critical patent/ATE332364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00906444T 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung ATE332364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902167 1999-02-22

Publications (1)

Publication Number Publication Date
ATE332364T1 true ATE332364T1 (de) 2006-07-15

Family

ID=9542357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906444T ATE332364T1 (de) 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung

Country Status (8)

Country Link
US (1) US7264958B1 (de)
EP (1) EP1155120B1 (de)
JP (2) JP4802366B2 (de)
AT (1) ATE332364T1 (de)
AU (1) AU774437B2 (de)
CA (1) CA2364934C (de)
DE (1) DE60029195T2 (de)
WO (1) WO2000050573A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1073721B1 (de) 1998-04-22 2005-08-31 Genvec, Inc. Effiziente reinigung von adenovirus
DK1407006T3 (da) * 2001-12-20 2005-12-12 Bavarian Nordic As Fremgangsmåde til indvinding og oprensning af poxvirus fra inficerede celler
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
AU2007272494B2 (en) 2006-07-14 2011-07-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
CA2675355C (en) 2007-01-30 2015-04-28 Transgene S.A. Papillomavirus vaccine
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
PL2382474T3 (pl) 2009-01-20 2015-08-31 Transgene Sa Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
HRP20140262T1 (hr) 2009-04-17 2014-04-25 Transgene Sa Biomarker za praä†enje pacijenata
MX337287B (es) 2009-07-10 2016-02-22 Transgene Sa Biomarcador para seleccionar pacientes y metodos relacionados.
MX2012001592A (es) 2009-08-07 2012-05-22 Transgene Sa Composicion para el tratamiento de la infección del virus de la hepatitis b.
EP2536829B1 (de) 2010-02-15 2016-04-06 Crucell Holland B.V. Verfahren zur Herstellung von adenoviralen Ad26-Vektoren
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2632562B1 (de) * 2010-10-27 2020-08-05 Philip Morris Products S.a.s. Verfahren zur erfassung virusähnlicher partikel aus pflanzen unter verwendung von expansionsbett- chromatografie
EP3202897B1 (de) 2010-12-09 2020-04-15 Institut Pasteur Diagnostische verwendung eines fusionspolypeptids, das ein virales protein und ein mgmt-enzym enthält
EP2747778B1 (de) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza-viren mit einem mutanten pb2-gensegment als lebende abgeschwächte impfstoffe
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP2872172B1 (de) 2012-07-10 2018-11-14 Transgene SA Impfstoff mit einem mykobakteriellen antigen
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
EP3831398A1 (de) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Onkolytische adenoviren, die mit heterologen genen ausgestattet sind
CA2936131A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
AU2016369485B2 (en) 2015-12-17 2024-02-01 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CA3033267A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
BR112019022108A2 (pt) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
CA3100004A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
AU2019344006B2 (en) 2018-09-21 2025-11-27 University Of Connecticut Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome
WO2020104691A1 (en) * 2018-11-22 2020-05-28 Fixed Phage Limited Production of immobilised bacteriophage
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4176087A1 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Verfahren zur bestimmung des ansprechens auf eine prostatakrebsbehandlung
US20230241530A1 (en) * 2022-02-01 2023-08-03 W. L. Gore & Associates, Inc. Affinity chromatography devices containing a heat treated fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328256A1 (de) * 1988-01-21 1989-08-16 Owens-Corning Fiberglas Corporation Glasfaser, überzogen mit Agarose, zur Verwendung als Säulenpackung oder chromatographisches Medium in Biotrennungen
GB8806605D0 (en) 1988-03-19 1988-04-20 Robinson E Composite adsorbents
SE9101149D0 (sv) 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
DE4128953A1 (de) * 1991-08-30 1993-03-04 Basf Ag Verfahren zur kultivierung von saeugerzellen im fliessbettreaktor
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6027888A (en) * 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
DE69739961D1 (de) 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
SE9700383D0 (sv) * 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
AU2583099A (en) 1998-02-04 1999-08-23 Sun Microsystems, Inc. Method and apparatus for efficient authentication and integrity checking using hierarchical hashing
EP1073721B1 (de) 1998-04-22 2005-08-31 Genvec, Inc. Effiziente reinigung von adenovirus

Also Published As

Publication number Publication date
CA2364934C (fr) 2011-10-18
JP2002536992A (ja) 2002-11-05
JP2011120596A (ja) 2011-06-23
US7264958B1 (en) 2007-09-04
WO2000050573A1 (fr) 2000-08-31
EP1155120A1 (de) 2001-11-21
EP1155120B1 (de) 2006-07-05
DE60029195T2 (de) 2007-06-28
CA2364934A1 (fr) 2000-08-31
AU2811800A (en) 2000-09-14
JP4802366B2 (ja) 2011-10-26
AU774437B2 (en) 2004-06-24
DE60029195D1 (de) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE332364T1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
ATE324436T1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE60114348D1 (de) Verfahren zur Reinigung von Gasen
DE60221619D1 (de) Verfahren zur Reinigung von Synthesegas
DE69637509D1 (de) Verfahren zur reinigung von faktor-ix
DE69908998D1 (de) Verfahren zur Herstellung von Kohlenstoff
DE69703957D1 (de) Verfahren zur Herstellung von kristallinen Ceroxidteilchen.
AU1811301A (en) Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
DE59800264D1 (de) Verfahren zur Herstellung von SiO2-Granulat
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE60120819D1 (de) Verfahren zur adsorptiven Trennung von Kohlendioxid
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE60203975D1 (de) Verfahren zur Herstellung von magnetischen Teilchen, magnetische Teilchen und magnetischer Werkstoff
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
AU2003279240A1 (en) Methods for purifying viral particles for gene therapy
DE60105209D1 (de) Verfahren zur Herstellung von niedrig substituierter Hydroxypropylcellulose-Partikeln
DE69931976D1 (de) Verfahren zur Herstellung von Aminophosphinen und Aminophosphinoxiden, Zwischenprodukte dafür
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril
DE60002020D1 (de) Verfahren zur Herstellen von hochreinem Xylitol
AU2003265052A1 (en) Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
DE59912502D1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155120

Country of ref document: EP